Background: In clinical trials, at the group level, results are usually reported as mean and
standard deviation of the change in score, which is not meaningful for most readers. Objective: …

Background Reduced duration of antibiotic treatment might contain the emergence of
multidrug-resistant bacteria in intensive care units. We aimed to establish the effectiveness of an …

Background: The patient acceptable symptom state (PASS) is the value beyond which patients
can consider themselves well. This concept can help in interpreting results of clinical trials…

Background In February, 2017, the US Food and Drug Administration approved the blood
infection marker procalcitonin for guiding antibiotic therapy in patients with acute respiratory …

Background Acute respiratory infections (ARIs) comprise a large and heterogeneous group
of infections including bacterial, viral and other aetiologies. In recent years, procalcitonin ‐ …

Background The timing of renal-replacement therapy in critically ill patients who have acute
kidney injury but no potentially life-threatening complication directly related to renal failure is …

Objective Tuberculosis (TB) is associated with anti–tumor necrosis factor (anti‐TNF) monoclonal
antibody (mAb) therapy, but whether this association is drug‐specific remains a concern…

Background Measurement of the degree of aortic valve calcification (AVC) using electron
beam computed tomography (EBCT) is an accurate and complementary method to …

Objective To estimate the minimum clinically important improvement (MCII) and patient
acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 …

Background. Procalcitonin algorithms may reduce antibiotic use for acute respiratory tract
infections (ARIs). We undertook an individual patient data meta-analysis to assess safety of …